SCHEMBL1483322

SCHEMBL1483322

COC(=O)CCCOc1ccc(-c2ccc(C=Cc3nc(-c4ccc(Cl)cc4Cl)cn3Cc3ccc(OC(F)(F)F)cc3)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 5/20 0.39
FFAR1 O14842 3/20 0.39
CYP2C9 P11712 1/20 0.39
SCN5A Q14524 1/20 0.39
MARS1 P56192 1/20 0.38
MAPT P10636 1/20 0.37
PTGS2 P35354 1/20 0.36
CNR1 P21554 3/20 0.35
PPARA Q07869 2/20 0.35
GCGR P47871 1/20 0.34
KCNA3 P22001 1/20 0.34
MMP2 P08253 1/20 0.34
MMP3 P08254 1/20 0.34
MMP7 P09237 1/20 0.34
MMP9 P14780 1/20 0.34
MMP8 P22894 1/20 0.34
MMP13 P45452 1/20 0.34
ARRB1 P49407 1/20 0.34
DRD2 P14416 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1483320 1.00 FFAR4 (0.39) FFAR4FFAR1CYP2C9SCN5AMARS1
SCHEMBL1481421 0.92 FFAR4 (0.48) FFAR4FFAR1CYP2C9SCN5AMARS1
SCHEMBL1481418 0.92 FFAR4 (0.48) FFAR4FFAR1CYP2C9SCN5AMARS1
SCHEMBL1482891 0.91 CNR1 (0.42) FFAR4FFAR1CYP2C9SCN5AMARS1
SCHEMBL1481637 0.91 CNR1 (0.42) FFAR4FFAR1CYP2C9SCN5AMARS1
SCHEMBL1481178 0.90 AGER (0.40) FFAR4FFAR1CYP2C9SCN5AMARS1
SCHEMBL1481176 0.90 AGER (0.40) FFAR4FFAR1CYP2C9SCN5AMARS1
SCHEMBL1481218 0.89 MAPT (0.42) MAPTPTGS2CNR1PPARAKCNA3
SCHEMBL1481219 0.89 MAPT (0.42) MAPTPTGS2CNR1PPARAKCNA3
SCHEMBL1481757 0.88 DRD2 (0.45) CYP2C9MARS1MAPTGCGRDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ FFAR4 2604/4885FFAR1 1810/4885CYP2C9 704/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ FFAR4 2604/4885FFAR1 1810/4885CYP2C9 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.